Withings is pushing smart scales into a new category with Body Scan 2, a device it calls a science backed longevity station. The pitch is big: a 90 second assessment that generates 60+ biomarkers and organizes them into a more actionable picture of cardiovascular and metabolic health.

Body Scan 2 is designed to deliver deeper insights beyond weight and body fat. Coverage highlights a longevity assessment across categories like heart performance, hypertension risk, arterial health, metabolic and cellular indicators, and glycemic regulation. The device uses multiple electrodes across the platform and a handle to collect more complete measurements.

Withings has listed Body Scan 2 at $599.95 in the U.S., with a planned release in Q2 2026, pending FDA clearance for certain metrics. The company has also noted availability through Withings, Amazon, and select retailers.

Two headline features, including hypertension risk notifications and a multi lead ECG capability, are pending FDA clearance. This is important because Withings is clearly positioning the device closer to preventative health monitoring than casual wellness tracking.

Body Scan 2 is aiming to be the most comprehensive consumer scale in the market. If the experience is as simple as promised and the health insights are credible, Withings could turn the bathroom scale into one of the most consistent health touchpoints people use all year.